- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Interventions
- adalimumab
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 6 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • New York, New York • Charlotte, North Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–38
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
- Interventions
- D-Galactose
- Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Interventions
- Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis
- Biological · Procedure · Other
- Lead sponsor
- Sumithira Vasu
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma
- Interventions
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 6 Months to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Acute Lymphoblastic
- Interventions
- CART 19
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kidney Disease, Glomerular Disease, Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Collapsing Glomerulopathy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Balance Training, Breathing and Stretching Exercises
- Other
- Lead sponsor
- Texas Woman's University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Houston, Texas • Sugar Land, Texas • Webster, Texas
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Adult Acute Lymphoblastic Leukemia, Interleukin-3 Receptor Subunit Alpha Positive, Minimal Residual Disease, Refractory Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis, Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes, Fludarabine Phosphate
- Drug · Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Interventions
- Abatacept, Normal Saline, D5W
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Interventions
- trascutaneous auricular vagus nerve stimulation, Sham device
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- New Hyde Park, New York • Philadelphia, Pennsylvania
- Conditions
- Idiopathic Nephrotic Syndrome
- Interventions
- Standard of Care, UrApp
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Minneapolis, Minnesota • Portland, Oregon
- Conditions
- Gastroesophageal Reflux
- Interventions
- Pantoprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 51
- States / cities
- Alabaster, Alabama • Huntsville, Alabama • Mesa, Arizona + 43 more
- Conditions
- Insomnia Disorder, Cognitive Functioning
- Interventions
- CBTi: Stimulus Control Core, CBTi: Sleep Restriction Core, CBTi: Sleep Compression Core
- Behavioral
- Lead sponsor
- Idaho State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Pocatello, Idaho
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
- Interventions
- WAL0921, Placebo
- Drug
- Lead sponsor
- Walden Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more